INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDV INDIVIOR PLC

Pre-Mkt 03-20 08:44:05 EDT

30.50

-0.03

-0.10%

盘前30.45

-0.05-0.16%

08:37 EDT

High30.99	Low30.00	Vol4.10M
Open30.32	D1 Closing30.53	Amplitude3.24%
Mkt Cap3.81B	Tradable Cap2.74B	Total Shares124.85M
T/O124.89M	T/O Rate4.56%	Tradable Shares89.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDV","market":"US","secType":"STK","nameCN":"INDIVIOR PLC","latestPrice":30.5,"timestamp":1773950400000,"preClose":30.53,"halted":0,"volume":4095410,"hourTrading":{"tag":"盘前","latestPrice":30.45,"preClose":30.5,"latestTime":"08:37 EDT","volume":642,"amount":19552.320576000002,"timestamp":1774010234877,"change":-0.05,"changeRate":-0.001639,"amplitude":0.031148},"delay":0,"changeRate":-0.0009826400262037713,"floatShares":89802878,"shares":124853897,"eps":0.981213,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"03-20 08:44:05 EDT","open":30.32,"high":30.99,"low":30,"amount":124885522.63902001,"amplitude":0.032427,"askPrice":30.98,"askSize":21,"bidPrice":30.13,"bidSize":21,"shortable":3,"etf":0,"ttmEps":0.981213,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774013400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":30.5,"preHourTrading":{"tag":"盘前","latestPrice":30.45,"preClose":30.5,"latestTime":"08:37 EDT","volume":642,"amount":19552.320576000002,"timestamp":1774010234877,"change":-0.05,"changeRate":-0.001639,"amplitude":0.031148},"postHourTrading":{"tag":"盘后","latestPrice":30.5,"preClose":30.5,"latestTime":"19:50 EDT","volume":123787,"amount":3775501.13,"timestamp":1773964242884,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6485107740387966,"impliedVol":0.4711,"impliedVolPercentile":0.316},"requestUrl":"/m/hq/s/INDV","defaultTab":"news","newsList":[{"id":"2620405838","title":"Indivior Issues $500 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405838","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405838?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:42","pubTimestamp":1773780132,"startTime":"0","endTime":"0","summary":"An update from Indivior ( ($INDV) ) is now available. On March 17, 2026, Indivior Pharmaceuticals, Inc. issued $500 million of 0.625% Convertible S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indivior-issues-500-million-convertible-senior-notes-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indivior-issues-500-million-convertible-senior-notes-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"gpt_icon":0},{"id":"2620609408","title":"Indivior Pharmaceuticals issues USD 500 million 0.625% convertible senior notes due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2620609408","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620609408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:08","pubTimestamp":1773778093,"startTime":"0","endTime":"0","summary":"Indivior issued USD 500 million of 0.625% convertible senior notes due 2031 under an indenture with U.S. Bank Trust Company. The company used part of the proceeds to prepay all amounts outstanding under a note purchase agreement with RBP Global Holdings, Indivior Global Holdings, Piper Sandler Finance, and lender parties, and terminated that agreement. The notes pay interest semi-annually and mature on March 15, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4SfFbT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","LU1894683264.USD","LU1894683348.USD","BK4007","LU0170899867.USD","BK4559","LU0053671581.USD","USB","LU2237438978.USD","IE00BFXG1179.USD","BK4588","PIPR","INDV","BK4585","LU1883839398.USD","BK4127","BK4504"],"gpt_icon":0},{"id":"2620479967","title":"Indivior-backed survey finds 58% of U.S. correctional facilities offer at least one FDA-approved MOUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2620479967","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620479967?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:02","pubTimestamp":1773763369,"startTime":"0","endTime":"0","summary":"Indivior reported results from a cross-sectional survey published in the Journal of Correctional Health Care assessing access to medications for opioid use disorder  in U.S. correctional facilities. The study, conducted with the National Commission on Correctional Health Care, surveyed 212 jails, prisons, and detention centers and found that 58% offered at least one FDA-approved MOUD. The survey found that jails were more than twice as likely as prisons to provide MOUD, and facilities in the West had more than triple the odds of offering MOUD compared with those in the Midwest. Respondents cited implementation barriers including stigma, abstinence-only approaches, limited provider training, and constrained budgets. Qualitative feedback highlighted needs for reentry support such as housing, care coordination, and expanded use of long-acting injectables and telehealth.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL29JcsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4007","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4112","NDAQ","INDV","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4588"],"gpt_icon":0},{"id":"2619887148","title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619887148","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619887148?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:26","pubTimestamp":1773433580,"startTime":"0","endTime":"0","summary":"Barbara Ryan, a director of Indivior Pharmaceuticals Inc., reported an acquisition of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5Mz5H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VEON","ULTA","RJF","HBAN","AMAT","CMCT","CVNX","VACH","KLAR","LVWR","INDV","IMM.AU","IBG","CCUP","CVNA","CRCD","BW","BIAF","PODD","PAR","SDHC","ICRC","AIFF","ARES","FITB","WDCX","CRCA","KYIV","ADBG","DOUG","INMD","CVNY","CRCO","AMPY","KLC","TVGN","OFRM","SANA","SVCO","CRVS","ESQ","ISPC"],"gpt_icon":1},{"id":"2619411877","title":"BUZZ-Indivior Pharma rebounds after upsized $450 mln convertible bond offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619411877","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619411877?lang=en_us&edition=fundamental","pubTime":"2026-03-13 22:01","pubTimestamp":1773410508,"startTime":"0","endTime":"0","summary":"BUZZ-Indivior Pharma rebounds after upsized $450 mln convertible bond offering** Indivior Pharmaceuticals INDV.O shares gap up as much as 4.3% to $32.18 early Fri after above-target haul** North Chesterfield, VA-based opioid use disorder treatment firm late Thurs announced pricing private offering of $450 mln 0.625% 5-yr convertible bonds ** Initial conversion price of $41.66 is 35% premium over stock's last close** INDV shares finished down 6% on Thurs after co announced $400 mln offering** Co intends to use ~$239 mln of net offering proceeds along with $102 mln of cash on hand to repay borrowings under term loan and revolver** It also plans to repurchase about 2.4 mln shares, ~$75 mln worth, to facilitate hedging by investors in the CBs** Stock last up 2.9% at $31.74. Shares down ~12% YTD after 189% gain in 2025** All 7 analysts are bullish including 2 \"strong buy\" ratings; median PT $48, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"gpt_icon":0},{"id":"2619598601","title":"Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619598601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619598601?lang=en_us&edition=fundamental","pubTime":"2026-03-13 08:30","pubTimestamp":1773361800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA4SNRXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618131529","title":"Indivior Pharmaceuticals Plans $400 Million Private Debt Offering; Shares Down Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131529?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:50","pubTimestamp":1773316221,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals  said Thursday it plans a $400 million private offering of convertible senior unsecured notes due March 15, 2031.The company expects to grant the initial purchasers a 30-day option to buy up to an additional $60 million of the notes.Indivior said it plans to use the net proceeds to help repay borrowings under and terminate the note purchase agreement that governs its term loan and revolving credit facility, among other things.The company's shares were down 5.3% in premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618713138","title":"Indivior announces proposed convertible senior notes offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618713138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618713138?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:37","pubTimestamp":1773315451,"startTime":"0","endTime":"0","summary":"Indivior (INDV) Pharmaceuticals announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/indivior-announces-proposed-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/indivior-announces-proposed-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618013661","title":"Indivior plans USD 400 million convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2618013661","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618013661?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:03","pubTimestamp":1773313391,"startTime":"0","endTime":"0","summary":"Indivior announced a proposed private offering of USD 400 million of convertible senior notes due 2031, with an option for initial purchasers to buy up to an additional USD 60 million. If fully exercised, the total issuance would be USD 460 million. Indivior said it plans to use about USD 239 million of net proceeds plus about USD 102 million of cash on hand to repay borrowings and terminate its term loan and revolving credit facility agreement. The company also expects to use up to about USD 75 million of net proceeds to repurchase common shares from certain note purchasers in concurrent private transactions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDLPxSC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","BK4588","BK4112","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4007"],"gpt_icon":0},{"id":"2618135721","title":"Indivior Pharmaceuticals, Inc - to Use $239 Mln Net Proceeds and $102 Mln Cash to Repay Borrowings","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135721?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUACDVGS0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618135714","title":"Indivior Pharmaceuticals, Inc - to Use up to $75 Mln Net Proceeds to Repurchase Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135714?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUACDVGS0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618135712","title":"Indivior Pharmaceuticals, Inc - Announces Intention to Offer $400 Mln Convertible Senior Notes Due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135712?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUACDVGS0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618136864","title":"Press Release: Indivior Announces Proposed Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618136864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618136864?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313200,"startTime":"0","endTime":"0","summary":"RICHMOND, Va., March 12, 2026  -- Indivior Pharmaceuticals, Inc.  today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031  in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended . Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes.The notes will be senior, unsecured obligations of Indivior, will accrue interest payable semi-annually in arrears and will mature on March 15, 2031, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Indivior will settle conversions by paying or delivering cash and, if applicable, shares of its common stock.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"gpt_icon":0},{"id":"2618940725","title":"Indivior announces findings from real-world evidence from study on Sublocade","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940725","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940725?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:12","pubTimestamp":1773234733,"startTime":"0","endTime":"0","summary":"Indivior (INDV) Pharmaceuticals announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Publ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/indivior-announces-findings-from-real-world-evidence-from-study-on-sublocade-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/indivior-announces-findings-from-real-world-evidence-from-study-on-sublocade-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2618365940","title":"Study links 12-month SUBLOCADE adherence to 42% lower annual non-MOUD medical costs in opioid use disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2618365940","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618365940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:02","pubTimestamp":1773234141,"startTime":"0","endTime":"0","summary":"Indivior reported results from a real-world, retrospective observational study published in Frontiers in Public Health that assessed healthcare utilization and costs among commercially insured patients with opioid use disorder by medication adherence. Patients adherent to the monthly injectable buprenorphine SUBLOCADE for 12 months had USD 35,761 in adjusted annual non-MOUD medical costs, which was 42% lower than patients adherent to other forms of MOUD . The analysis also found that SUBLOCADE-adherent patients had the lowest inpatient admissions and emergency department visits across the treatment groups. The study is titled Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6Mpxcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","IE00B64PRP62.GBP","INDV","IE00BGHQF748.EUR","SG9999014005.SGD","BK4112","NDAQ","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4007","SG9999014021.USD"],"gpt_icon":0},{"id":"2618390942","title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618390942","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618390942?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:13","pubTimestamp":1773231180,"startTime":"0","endTime":"0","summary":"Barbara Ryan, a director of Indivior Pharmaceuticals Inc., reported an acquisition of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL4lQdfX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2614866563","title":"Indivior (INDV) Gets a Buy from Northland Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2614866563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614866563?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:35","pubTimestamp":1772213728,"startTime":"0","endTime":"0","summary":"In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Indivior, with a price target of $50.00. According to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/indivior-indv-gets-a-buy-from-northland-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/indivior-indv-gets-a-buy-from-northland-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2614303488","title":"Indivior: Structural Earnings Upgrade and Long-Term Growth Visibility Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614303488?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:35","pubTimestamp":1772192125,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on INDV stock, giving a Buy rating yesterday. Brandon Folkes has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/indivior-structural-earnings-upgrade-and-long-term-growth-visibility-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/indivior-structural-earnings-upgrade-and-long-term-growth-visibility-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INDV"],"gpt_icon":0},{"id":"2614003525","title":"Indivior Earnings Call: Profits Surge as SUBLOCADE Leads","url":"https://stock-news.laohu8.com/highlight/detail?id=2614003525","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614003525?lang=en_us&edition=fundamental","pubTime":"2026-02-27 08:07","pubTimestamp":1772150848,"startTime":"0","endTime":"0","summary":"Indivior plc (($INDV)) has held its Q4 earnings call. Read on for the main highlights of the call. Indivior’s latest earnings call struck a distinc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indivior-earnings-call-profits-surge-as-sublocade-leads?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indivior-earnings-call-profits-surge-as-sublocade-leads?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indivior.com","stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.1223},{"period":"3month","weight":-0.1338},{"period":"6month","weight":0.355},{"period":"1year","weight":2.0653},{"period":"ytd","weight":-0.1499}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.021864},{"month":2,"riseRate":0.583333,"avgChangeRate":0.011788},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.007396},{"month":4,"riseRate":0.818182,"avgChangeRate":0.02245},{"month":5,"riseRate":0.909091,"avgChangeRate":0.072883},{"month":6,"riseRate":0.454545,"avgChangeRate":0.053237},{"month":7,"riseRate":0.8,"avgChangeRate":0.171847},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014379},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.095405},{"month":10,"riseRate":0.363636,"avgChangeRate":0.007009},{"month":11,"riseRate":0.545455,"avgChangeRate":0.010295},{"month":12,"riseRate":0.636364,"avgChangeRate":0.020229}],"exchange":"NASDAQ","name":"INDIVIOR PLC","nameEN":"INDIVIOR PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INDIVIOR PLC,INDV,INDIVIOR PLC股票,INDIVIOR PLC股票老虎,INDIVIOR PLC股票老虎国际,INDIVIOR PLC行情,INDIVIOR PLC股票行情,INDIVIOR PLC股价,INDIVIOR PLC股市,INDIVIOR PLC股票价格,INDIVIOR PLC股票交易,INDIVIOR PLC股票购买,INDIVIOR PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}